20.6 C
New York

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy in adolescents

Published:


An Israeli health worker displays a vial of the Pfizer/BioNTech COVID-19 vaccine for children, at the Meuhedet Healthcare Services Organisation in Tel Aviv on November 22, 2021. — AFP
An Israeli health worker displays a vial of the Pfizer/BioNTech COVID-19 vaccine for children, at the Meuhedet Healthcare Services Organisation in Tel Aviv on November 22, 2021. — AFP
  • A two-dose series of vaccine was 100% effective against COVID-19.
  • It was measured 7 days through over 4 months after second dose.
  • Vaccine was authorised for emergency use in people aged 12-15 years by US in May.

Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorised for emergency use in people aged 12-15 years by the US Food and Drug Administration in May, and granted full approval for use in people aged 16 and above in August.



For Latest Updates Follow us on Google News

**If you have any Query Related This Post then here is the Source Link**

Related articles

Recent articles